Clinical Evaluation of GENEX® DS in Instrumented Posterolateral Fusion
- Conditions
- SpondylolisthesisDegenerative Disc DiseaseStenosis
- Registration Number
- NCT02317185
- Lead Sponsor
- Spine Wave
- Brief Summary
The overall goal of this clinical study is to characterize the fusion rate of geneX® ds bone graft substitute in comparison to autograft, which is considered the gold standard for posterolateral fusion. Assessments are made using AP and Lateral x-rays, F/E x-rays, and CT scans geneX® ds has been cleared by the FDA for use in these procedures; however this study will allow more detailed characterization of geneX® ds performance in the long-term (1 year). By using the patient as their own control, direct comparison to autograft can be performed while minimizing other variables.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2
- Men or women 18-75 years of age
- Have ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol
- Have a spinal condition of the lumbar spine (L1-S1) requiring instrumented posterolateral fusion at one or two levels
- Patients undergoing instrumented fusion for trauma, tumor, psuedoarthrosis, or same- - level recurrent stenosis
- Patients where placing graft material on both sides (posterolateral gutters) is not possible, for example in the case of a complete facetectomy
- Patients requiring instrumented fusion in the cervical or thoracic spine
- Extraspinal cause of back pain such as trauma, infection, instrumentation failure, or neoplasm
- Severe degenerative bone disease
- Hypercalcemia
- Active local or systemic infection
- Morbid obesity defined as BMI > 40
- Patients who are pregnant / able to become pregnant and not following a reliable contraceptive method
- Uncooperative patients who can't or won't follow post-operative instructions including individuals who abuse drugs or alcohol
- Anatomy or other factors that prohibit safe surgical access to the surgical site
- Allergy or sensitivity to any component of the treatment procedure
- Inadequate tissue coverage over the operative site
- Inadequate bone stock or bone quality
- Fever or leukocytosis
- Uncorrectable coagulopathy or hemorrhagic diathesis
- Uncontrolled diabetes
- Severe vascular disease or cardiopulmonary conditions that present prohibitive anesthesia risk
- Neuromuscular disease or disorder
- Mental illness
- Has an active workman's compensation lawsuit
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fusion 1 year Fusion will be assessed by a single, independent radiologist using study required x-rays (AP, Lateral, Flexion-Extension) and CT scans. On xray, fusion will be graded for bridging bone and lucencies. Flexion extension x-rays will also be evaluated to determine translational and angular motion. For these evaluations, fusion is defined as translational motion \< 3mm and angular motion \< 5º.CT assessments of fusion will include qualitative evaluation of the continuity of trabecular bone between the transverse processes, cortication at the peripheral edges of the fusion masses, and the absence of identifiable radiographic clefts. Quantitative volumetric measurements of the fusion mass will be performed by outlining the fusion area in each cross-sectional slice and summing all slices.
- Secondary Outcome Measures
Name Time Method Complications 1 year Complications will be assessed by evaluating all reported adverse events. The analysis will be descriptive only.
Trial Locations
- Locations (2)
Hospital for Special Surgery
🇺🇸New York, New York, United States
Carolina Neurosurgery and Spine Associates
🇺🇸Charlotte, North Carolina, United States